Introduction
The renin angiotensin system (RAS) has traditionally been linked to the regulation of the salt and water homoeostasis. The effector peptide of the RAS, angiotensin II, binds at least to two receptor subtypes, referred to as the AT 1 and the AT 2 receptors. The classical peripheral actions of angiotensin II, which include vasoconstriction, facilitation of sympathetic transmission and renal salt and water retention are mediated by the AT 1 receptor. These actions can be regarded as compensatory mechanisms to preserve salt and water, and maintain electrolyte balance and adequate organ perfusion, in the face of water and salt loss.
In the last three decades, evidence has accumulated that angiotensin II can be formed in various tissues, such as brain, kidney, adrenal gland, heart and blood vessels. The brain has long been recognised as a site of tissue RAS activity, and it has been firmly established that angiotensin II is synthesised Correspondence: J Culman, MD, Institute of Pharmacology, Christian-Albrechts-University of Kiel, Hospitalstrasse 4, 24105 Kiel, Germany. E-mail: juraj.culman.Ȱpharmakologie.uni-kiel.de in the brain independently of peripheral sources. Angiotensin II acts on brain structures localised inside and outside the blood-brain barrier to induce drinking behaviour and natriuresis, stimulate vasopressin release, modulate sympathetic outflow to the periphery, and attenuate the baroreceptor reflex. Several lines of evidence suggest that inappropriate RAS activity in the brain may contribute to the development and maintenance of arterial hypertension.
During the past 10 years, much has been learnt about neuronal effects of angiotensin II that are not directly related to the central control of fluid and electrolyte homoeostasis and the regulation of blood pressure. In addition, numerous findings have demonstrated that angiotensin II, acting via the AT 2 receptor, may modulate embryonic development, tissue regeneration and protection, and initiate processes leading to programmed cell death (apoptosis). There is also substantial evidence that the AT 2 receptor can offset or counteract the effects mediated by the AT 1 receptor, for example on cell proliferation, water intake and blood pressure. 1, 2 This paper reviews the mechanisms of action and function of angiotensin-containing pathways in the
Components of the RAS in the brain
Angiotensin II in the brain is generated from angiotensinogen by an enzymatic cascade involving renin and angiotensin converting enzyme (ACE). The expression of renin in the brain has been clearly demonstrated using various biochemical and immunohistochemical techniques. The enzyme is synthesised in neurones and is present in high concentrations in nerve terminals. ACE has also been found in the synaptosomal fraction of brain tissue with high concentrations in the lamina terminalis and the circumventricular organs, hypothalamus and some brain stem nuclei. Angiotensinogen is mostly found extracellularly, and the mRNA encoding for angiotensinogen is predominantly localised in glial cells, although the peptide is also present in some neuronal populations. 3, 4 These findings suggest that angiotensin II is formed extracellularly in the brain. However, the fact that angiotensin II in the brain can be found almost exclusively within synaptic vesicles in nerve endings favours an intracellular formation of angiotensin II. Another unsolved question seems to be the lack of abundant renin expression in those brain areas where mRNA encoding for angiotensinogen is highly expressed and angiotensin II is present in high concentrations. In general, angiotensin I levels are low in the brain, which suggests that angiotensin II can be formed directly from angiotensinogen, rather than by the enzymatic activity of renin. Non-renin, non-ACE pathways involving acid proteases have been described. 5 Alternatively, renin expression may be strongly controlled to avoid a permanently high level of renin activity in brain areas abundant in angiotensinogen. 6 
Angiotensin pathways in the brain
The distribution of angiotensin peptides and their receptors is intimately linked to the brain areas associated with central regulation of fluid and salt homoeostasis and blood pressure control. Angiotensin II is a principal neurotransmitter within the lamina terminalis and its neuronal connections to other brain regions related to central cardiovascular control including the hypothalamic nuclei. Angiotensin II-stained cell bodies are prominent in the paraventricular and supraoptic nuclei. The neurosecretory cells in these regions, which synthesise vasopressin, lie within a network of angiotensinimmunoreactive fibres and terminals. 7, 8 In addition, cell groups positively stained for angiotensin II are located in the stria terminalis and in the medial nucleus of the amygdala. Angiotensin receptors have also been found in the hindbrain regions involved in the modulation of sympathetic vasomotor tone, despite the fact that the only site where
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angiotensin II-stained cells were found in the medulla was the nucleus of the solitary tract.
9

Angiotensin receptors and signal transduction pathways
In the adult brain, structures related to the regulation of body fluid homoeostasis and blood pressure express mainly or exclusively AT 1 receptors. As already mentioned, the AT 1 receptor mediates virtually all of the known physiological actions of angiotensin II in the brain, such as the regulation of arterial blood pressure and vasopressin release, electrolyte and water balance, thirst and hormone secretion (Figure 1 ). 10 The signalling pathways of the AT 1 receptor are well understood. They include the classic cascades activated by G proteins, resulting in increases of intracellular calcium and activation of protein kinase C. These signalling pathways are responsible for the generation and mediation of immediate responses, such as the release of vasopressin and oxytocin from the posterior pituitary. Other signalling pathways initiated by angiotensin II binding to the AT 1 receptor are phosphorylation-dependent reactions, some of which involve increased expression of inducible transcription factors such as c-Fos and c-Jun. These signalling cascades are believed to be involved in AT 1 receptor-mediated cell growth.
11 Activation of periventricular AT 1 receptors in the rat brain induces expression of transcription factors in all brain regions nuclei involved in cardiovascular control and osmoregulation.
11
A variety of signalling mediators have been described for the AT 2 receptor. The AT 2 receptor seems to be coupled to the G i protein, and the signalling mechanisms involve inhibition of mitogenactivated protein kinases, alteration in intracellular cGMP levels and inhibition of phosphorylation. Recent findings indicate that angiotensin II, acting via AT 2 receptors, is involved in the regulation of pro-and/or antiapoptotic events ( Figure 1 ). Saralasin, the first specific peptide antagonist of angiotensin receptors, interacts with both angiotensin receptor subtypes. Its therapeutic potential was limited by its short duration of action, poor oral bioavailability and partial agonist activity. In the late 1980s and early 1990s, a number of selective, non-peptide antagonists of AT 1 receptors were developed. These compounds selectively block the AT 1 receptor, while leaving the AT 2 receptor unaffected. The selective non-peptide AT 1 receptor antagonists have been proven to be safe and very effective agents in the treatment of hypertension and other cardiovascular diseases.
Several selective and high-affinity AT 1 receptor antagonists are currently available, including candesartan, eprosartan, irbesartan, losartan, telmisartan and valsartan. These compounds differ pharmacologically in terms of their affinity for the AT 1 receptor and in the duration of the receptor blockade. In in vitro binding studies, candesartan has a remarkably high affinity for the AT 1 receptor, compared with other antagonists. In general, the inhibition of AT 1 receptors by these antagonists is competitive and reversible. However, some AT 1 receptor antagonists, such as candesartan, have been found to dissociate extremely slowly from the receptor. Slow dissociation seems to be sufficient to produce insurmountable inhibition since insurmountable antagonism is characterised by a long-lasting inhibition of the receptor by the antagonist. In contrast to candesartan, losartan is a surmountable antagonist, whereas EXP3174, the active metabolite of losartan, valsartan and irbesartan exhibit different degrees of insurmountable inhibition. 12 Relative to other AT 1 receptor antagonists, candesartan exerts a longlasting blockade of the AT 1 receptor.
While the antihypertensive effects of AT 1 receptor antagonists have mainly been ascribed to inhibition of AT 1 receptors in the periphery, evidence has accumulated that inhibition of central AT 1 receptors may also contribute to the effects of these compounds on blood pressure. 13 Furthermore, effective and long-lasting blockade of central AT 1 receptors may protect against stroke and provide therapeutic benefits for patients suffering from brain ischaemia (see below).
In our laboratory, we have studied the access of systemically administered AT 1 receptor antagonists to brain AT 1 receptors. Both losartan and irbesartan, administered intravenously or orally, dosedependently attenuated central effects of angiotensin II (increases in mean arterial pressure, drinking and the release of vasopressin). At up to 60 min after systemic application, irbesartan appeared to penetrate the blood-brain barrier more effectively than losartan. However, even with high doses, complete inhibition of central angiotensin II effects was never achieved with either compound.
14 Moreover, the inhibition of brain AT 1 receptors following systemic treatment with irbesartan is short-lasting (up to 6 h). We have also demonstrated that telmisartan can penetrate the blood-brain barrier in a dose-and time-dependent manner to inhibit centrally mediated effects of angiotensin II. Compared with losartan and irbesartan, telmisartan is more liphophilic and this may explain its greater potency at brain AT 1 receptors following systemic application. 15 In our studies, candesartan produced the most effective inhibition of brain AT 1 receptors. Candesartan produced a complete, 24-h, blockade of centrally mediated angiotensin II effects at doses 5-10 times lower than the losartan or irbesartan doses required to inhibit central angiotensin II activity. 16 Chronic systemic treatment with candesartan also dose-dependently decreased AT 1 binding in brain areas localised outside, as well as inside, the bloodbrain barrier. 17 The effective and long-lasting blockade of brain AT 1 receptors displayed by candesartan may be attributed to the insurmountable antagonism, characterised by tight binding and slow dissociation from the receptor. This suggests that systemically administered candesartan may exhibit a long duration of action in the brain.
The brain RAS: cardiovascular effects and hypertension
Stimulation of angiotensin receptors in the brain results in vasopressin release, modulation of sympathoadrenal activity and inhibition of the baroreceptor reflex. 6 An increase in blood pressure can be observed when angiotensin II is injected into the lateral ventricle or distinct forebrain areas. Angiotensin II injected into the cerebral ventricles primarily activates neurons in the circumventricular organs, which project directly or indirectly to vasopressinsynthesising neurones in the paraventricular and supraoptic nuclei. The pressor response to intracerebroventricular angiotensin II is therefore initially mediated by vasopressin. 18 Angiotensin II acts as a neurotransmitter in some of the neuronal circuits innervating the neurosecretory cells in the hypothalamic paraventricular and supraoptic nuclei. 9 AT 1 receptors predominate in these hypothalamic regions 19 and mediate the pressor response to the peptide. The mechanisms involved in vasopressin secretion following intracerebroventricular administration of angiotensin II comprise noradrenaline release from nerve endings and stimulation of postsynaptic ␣-adrenoceptors localised on vasopressin-synthesising neurones in the paraventricular and supraoptic nuclei. 7 While the role of noradrenaline and ␣-adrenoceptors in the paraventricular and supraoptic nuclei in the mediation of vasopressin release following injection of angiotensin II into the cerebral ventricles has been firmly established, the mechanisms responsible for vasopressin release after direct stimulation of AT 1 receptors by angiotensin II in these regions are poorly understood. Studies have failed to demonstrate expression of AT 1 receptors in vasopressinsynthesising neurones in the magnocellular part of the paraventricular nucleus, although injection of angiotensin II into this region elicits an immediate increase in circulating vasopressin, which can be completely inhibited by prior injection of losartan. 19, 20 In addition to the forebrain sites of action, angiotensin II can act in the cardiovascular centres of the medulla to control blood pressure. The area postrema, the nucleus of the solitary tract and the rostral ventrolateral medulla appear to be the principal sites of action. All of these brain regions contain high densities of AT 1 receptors. The area postrema, which receives its blood supply from the vertebral arteries, is considered to monitor blood-borne angiotensin II; microinjection of the peptide into the area postrema produces a pressor response. 21 Angiotensin II has also been reported to modify the baroreflex by acting in the nucleus of the solitary tract. Interestingly, microinjection of angiotensin II into the nucleus of the solitary tract causes a depressor response at low doses, and a pressor response at high doses. Blood-borne angiotensin II can modify the baroreflex via neural pathways from the area postrema to the nucleus of the solitary tract. 22 Excitation of the rostral ventrolateral medulla produces an increase in blood pressure due to activation of sympathetic vasoconstrictor nerves, tachycardia and the release of catecholamines from the adrenal medulla. [22] [23] [24] [25] [26] An overactive brain RAS has been implicated in the development and maintenance of high blood pressure in spontaneously hypertensive rats (SHR). In SHR, the central RAS is activated, as demonstrated by increased formation of angiotensin II and increased AT 1 receptor expression in the brain. 4 Surprisingly, results concerning the blood pressure lowering effects of AT 1 -receptor inhibition in the brain are equivocal. In conscious adult SHR, acute or chronic inhibition of brain AT 1 receptors with losartan or candesartan failed to lower blood pressure. 27, 28 In contrast, Kamitani et al reported a reduction of high blood pressure after blockade of brain AT 1 receptors in nephrectomised SHR. 29 Similarly, antisense inhibition of mRNA encoding for the AT 1 receptor in the brain reduced hypertension in SHR. 13 Furthermore, normotensive rats developed hypertension following in vivo gene transfer of human ACE. 30 The exact mechanisms by which increased RAS activity in the brain contributes to the development of hypertension are not known. Recent findings indicate that angiotensin II-induced suppression of the afferent feedback from baroreceptors may represent one of the mechanisms by which elevated central angiotensin II activity could lead to hypertension. 31 Central effects of AT 1 receptor blockers may thus contribute, at least partly, to the effects of these compounds on blood pressure.
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Neuronal regeneration and tissue repair
The recognition that angiotensin II, acting via AT 2 receptors, may modulate tissue regeneration and protection, differentiation and processes leading to programmed cell death 10 represents the most exciting discovery during the last decade. Since it has become apparent that activation of AT 2 receptors plays a role in wound healing and repair in peripheral tissues, the attention of investigators has turned to the processes occurring after neuronal injury. Adult neurones do not usually reinnervate their target regions after injury. However, if they are supplied with growth-promoting substances, they can generate new processes over longer distances and reinnervate their target regions. Recent studies have demonstrated that following sciatic nerve injury, mRNA encoding for the AT 2 receptor is up-regulated in sciatic nerve segments, and that this coincides with the successful regeneration of nerve fibres. 32 In the in vivo optic nerve crush model, angiotensin II induced a concentration-dependent outgrowth of neurites; this effect was also mediated by the AT 2 receptor, since the regeneration process was paralleled by a time-dependent increase in AT 2 receptor mRNA expression in the retina and the crushed optic nerve. 33 These findings point to an unexpected role of angiotensin II and the AT 2 receptor in the regeneration processes following neuronal injury. Moreover, these data provide direct evidence that stimulation of AT 2 receptors can promote axonal regeneration in vivo after neuronal lesions.
Ischaemic stroke
Ischaemic stroke results from a transient or permanent reduction or interruption of cerebral blood flow. Both neuronal necrosis and apoptosis can be observed after brain ischaemia. Some brain cells are lost immediately, whereas cells in the penumbra (the area surrounding the ischaemic focus) are severely damaged and remain in a compromised state for several hours. Brain damage continues for days after the ischaemic event.
Cerebral ischaemia also leads to alteration in gene expression, which is under the control of inducible transcription factors. These transcription factors may provide a direct link between extracellular signals activating signal transduction pathways and the initiation of intracellular molecular and metabolic events leading to delayed neuronal death.
During the past decade, a number of studies have indicated that the brain RAS may be involved in the initiation and regulation of processes occurring during and after brain ischaemia. Treatment with ACE inhibitors or AT 1 receptor antagonists has been reported to prevent the occurrence of stroke in SHR or salt-loaded Dahl salt-sensitive rats, or to reduce the infarction volume after carotid artery occlusion. 34, 35 It is generally considered that ACE inhibitors protect against brain ischaemia primarily by reducing blood pressure. However, several lines of evidence suggest that additional effects may also be involved. ACE inhibitors have been reported to exert beneficial effects on the metabolic and circulatory derangement following cerebral ischaemia in SHR, and to improve the recovery from cerebral ischaemia in normotensive rats. 36, 37 Autoregulation of cerebral blood flow is impaired during brain ischaemia, and the neuroprotective effects of ACE inhibitors may be at least partly related to the normalisation of cerebrovascular autoregulation. In humans, cerebral blood flow is similar in normotensive and hypertensive individuals, due to an increased cerebrovascular resistance in hypertensive subjects. As a result of this increased resistance, the arteries display hypertrophy and lose the capability to dilate. The impaired dilatation of cerebral vessels at lower blood pressures results in a shift of the upper and lower limits of autoregulation to the right. ACE inhibitors have been shown to shift the limits of cerebral autoregulation to lower blood pressure levels in normotensive rats and in SHR. 38 Recent findings indicate that AT 1 receptor blockers produce similar effects. Acute administration of the AT 1 receptor blocker candesartan, at a dose that did not influence baseline cerebral blood flow, shifted the autoregulation curve towards lower blood pressure in both normotensive rats and SHR. 39 It has been further demonstrated that chronic treatment of stroke-prone SHR with candesartan reduces the incidence of stroke in these rats without affecting blood pressure. 40 Nishimura et al 41 attempted to clarify the role of AT 1 receptors in the control of cerebral blood flow in genetically hypertensive rats during cerebral ischaemia. Candesartan was used in these studies because of its potency at the AT 1 receptor and because it had previously been reported to completely normalise the cerebrovascular autoregulatory curve in these rats. 39 Pretreatment of SHR with candesartan for 2 weeks resulted in almost complete inhibition of AT 1 receptors in the cerebral arteries and in the brain areas involved in the central regulation of cerebral blood flow and the sympathetic system. In SHR exposed to temporary carotid occlusion followed by reperfusion, candesartan reduced the volume of injury predominantly in the affected cortical areas. 41 The proposed mechanisms involve increasing vasodilation and preventing the decrease in blood flow in the marginal zone of ischaemia. The observed reductions in cerebral oedema immediately after carotid occlusion, and in the infarction volume, probably resulted from the normalisation of cerebrovascular autoregulation in the marginal ischaemic zone. 42 AT 1 receptor blockers may also improve recovery from stroke by mechanisms independent of cerebrovascular autoregulation or blood pressure reduction. We have demonstrated that long-term blockade of brain AT 1 receptors by irbesartan and losartan improves neurological outcome of focal cerebral ischaemia, markedly reduces the expression of the transcription factors c-Fos and c-Jun in the parietal and piriform cortices on the ligated side of the brain, and completely abolishes ischaemia-induced c-Fos expression in the hippocampus. 43 The AT 1 receptor blockers were infused into the cerebral ventricles over a 5-day period before the induction of ischaemia, at a dose which effectively inhibited brain but not vascular AT 1 receptors. 43 In further studies we showed that systemic pretreatment of normotensive rats with candesartan, at doses which did not affect the arterial blood pressure, improved the recovery from cerebral ischaemia and reduced the volume of ischaemic injury (Figure 2 ; Groth et al unpublished results). Together, these findings demonstrate that AT 1 receptor blockers may improve the recovery from stroke by restoration of blood flow after ischaemia and by blocking the biochemical and metabolic changes at the ischaemic cascade level.
We have also investigated the role of AT 2 receptors during and after focal brain ischaemia. Although long-term inhibition of brain AT 2 receptors did not affect the recovery from stroke, it prevented the beneficial effects of AT 1 receptor blockade (Culman et al, unpublished results) . AT 1 receptor blockade exposes AT 2 receptors to increased concentrations of angiotensin II. Activation of AT 2 receptors in brain tissue that has undergone ischaemic injury may initiate neuroregenerative events or induce apoptosis in severely damaged neurones. Both these effects are important for the recovery from stroke. 44 
Outlook
Intensive research over the past 10 years has yielded new insights into the role of angiotensin receptors in neuronal tissue. AT 2 receptors have been implicated in processes occurring in neuronal tissue during development, regeneration or repair, but the actual contribution of these receptors to the regulation of events associated with these processes remains to be clearly defined. As effects mediated by AT 2 receptors generally counteract those mediated by AT 1 receptors, the net effect of angiotensin II in neuronal tissue may therefore depend on the numbers and expression of both receptor types. The neurotrophic actions of AT 2 receptor stimulation may provide a basis for the design of new therapeutic strategies in the failure of axonal regeneration or in the treatment of neurodegenerative disorders and stroke. Similarly, the finding that AT 1 receptor blockers cross the blood-brain barrier and improve neurological outcome and prevent brain injury following brain ischaemia may provide a basis for new therapeutic strategies in the prevention and treatment of stroke. The potential clinical relevance of these findings is underlined by the increasing use of AT 1 receptor blockers in antihypertensive treatment and the prevention of end-organ damage related to hypertension.
